One Saudi Sidr Honey Beat Penicillin Against E Coli in Lab Test

• All three Sidr honey samples converted silver nitrate into spherical silver nanoparticles, confirmed by electron microscopy, with particle sizes ranging from about 50 to 90 nanometers depending on the source.
• In a lab dish assay, honey from Rijal Ulma, Saudi Arabia produced a larger bacterial inhibition zone against E coli than a penicillin control, and adding the silver nanoparticles nearly doubled that zone's size.
• In a preliminary rat cell study, the same Saudi honey stimulated normal spleen cell growth, while honey from Pakistan and a second Saudi source suppressed it, showing the three samples did not behave alike despite sharing the Sidr name.
• None of the honeys alone affected Hela cervical cancer cells in culture, but honey combined with the silver nanoparticles did slow their growth.
• All three honeys, alone or with nanoparticles, reduced growth of HepG2 liver cancer cells in vitro, an effect that grew stronger once nanoparticles were added.

Three jars of honey, all labeled Sidr, all from the same tree species, produced results that pulled in opposite directions once they reached a lab bench.

A preliminary in vitro and animal cell study tested Sidr honey, Ziziphus spina christi, collected from three sources, two from Rijal Ulma in Saudi Arabia and one from Pakistan, and found that despite sharing a name and a floral origin, the three samples behaved differently across nearly every measure the researchers ran.

Researchers diluted each honey to 20 percent and ran it through several tests: bacterial inhibition assays against common pathogens, a cell proliferation assay using normal rat spleen cells, and cancer cell tests using Hela and HepG2 lines. They also mixed each honey with silver nitrate to see whether it could drive the chemical reaction that produces silver nanoparticles, a green chemistry technique researchers use to make nanoparticles without harsh industrial solvents.

The results held real variety. Honey from one Saudi source inhibited E coli more effectively than the study's penicillin control, something the other two samples did not manage. That same honey encouraged normal spleen cells to multiply, while the Pakistani sample and the second Saudi sample, drawn from a different bee species, did the reverse and suppressed spleen cell growth. All three, meanwhile, agreed on one thing: none of them affected Hela cancer cells on their own, yet all three slowed the growth of HepG2 liver cancer cells, an effect that became more pronounced once each honey was combined with silver nanoparticles it had helped produce.

This kind of variability is exactly what you would expect from a natural product shaped by geography and the bees that make it. Honey composition shifts with region, plant source, and even which bee subspecies did the foraging, and this study is a fairly direct demonstration of that: identical labeling did not mean identical behavior in the lab. It also points to a genuinely interesting use for honey beyond food or wound care, as a plant free reducing agent capable of assembling metal nanoparticles.

None of this translates to a treatment or a health claim. These were laboratory and cell culture experiments, not trials in humans, and a honey that inhibits cancer cells in a dish or produces nanoparticles in a flask is a long way from a therapy. The researchers themselves flagged this, noting that one of the honeys stimulated growth in one cell type while inhibiting another, a reminder that "anticancer" in this context describes a lab observation, not a guarantee.

What the study does capture well is the idea that source matters. Sidr honey, the variety several Tayab offerings draw from, is one where provenance and testing, not just the name on the label, are what separate one jar from another.